Cargando…
Decreased eukaryotic initiation factors expression upon temozolomide treatment—potential novel implications for eIFs in glioma therapy
PURPOSE: Since glioma therapy is currently still limited until today, new treatment options for this heterogeneous group of tumours are of great interest. Eukaryotic initiation factors (eIFs) are altered in various cancer entities, including gliomas. The purpose of our study was to evaluate the pote...
Autores principales: | Krassnig, Stefanie, Leber, Stefan L., Orthmann, Andrea, Golob-Schwarzl, Nicole, Huber, Heinrich Johann, Wohlrab, Christina, Skofler, Christina, Pennauer, Mirjam, Raicht, Andrea, Birkl-Toeglhofer, Anna Maria, Naumann, Michael, Mahdy-Ali, Kariem, von Campe, Gord, Leoni, Marlene, Alcaniz, Joshua, Hoffmann, Jens, Wälchli, Thomas, Weis, Serge, Benesch, Martin, Haybaeck, Johannes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638187/ https://www.ncbi.nlm.nih.gov/pubmed/37907716 http://dx.doi.org/10.1007/s11060-023-04451-y |
Ejemplares similares
-
A Profound Basic Characterization of eIFs in Gliomas: Identifying eIF3I and 4H as Potential Novel Target Candidates in Glioma Therapy
por: Krassnig, Stefanie, et al.
Publicado: (2021) -
Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma
por: Skofler, Christina, et al.
Publicado: (2021) -
The Prognostic Significance of Eukaryotic Translation Initiation Factors (eIFs) in Endometrial Cancer
por: Smolle, Maria Anna, et al.
Publicado: (2019) -
Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures
por: Alcaniz, Joshua, et al.
Publicado: (2023) -
Hepatic gene expression explains primary drug toxicity in bipolar disorder
por: Birkl-Toeglhofer, Anna Maria, et al.
Publicado: (2019)